Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1958 1
1959 1
1962 1
1974 1
1975 4
1976 2
1977 1
1978 3
1979 8
1980 2
1981 2
1982 3
1983 3
1985 3
1986 2
1987 2
1989 1
1991 1
1992 4
1993 1
1994 1
1995 2
1996 3
1997 6
1998 4
1999 7
2000 7
2001 4
2002 18
2003 19
2004 22
2005 31
2006 38
2007 40
2008 65
2009 91
2010 104
2011 116
2012 114
2013 115
2014 127
2015 166
2016 161
2017 173
2018 204
2019 214
2020 259
2021 394
2022 422
2023 413
2024 158

Text availability

Article attribute

Article type

Publication date

Search Results

3,124 results

Results by year

Filters applied: . Clear all
Page 1
EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update.
Hellmich B, Sanchez-Alamo B, Schirmer JH, Berti A, Blockmans D, Cid MC, Holle JU, Hollinger N, Karadag O, Kronbichler A, Little MA, Luqmani RA, Mahr A, Merkel PA, Mohammad AJ, Monti S, Mukhtyar CB, Musial J, Price-Kuehne F, Segelmark M, Teng YKO, Terrier B, Tomasson G, Vaglio A, Vassilopoulos D, Verhoeven P, Jayne D. Hellmich B, et al. Among authors: teng yko. Ann Rheum Dis. 2024 Jan 2;83(1):30-47. doi: 10.1136/ard-2022-223764. Ann Rheum Dis. 2024. PMID: 36927642
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.
Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, Boletis J, Bruce IN, Cervera R, Doria A, Dörner T, Furie RA, Gladman DD, Houssiau FA, Inês LS, Jayne D, Kouloumas M, Kovács L, Mok CC, Morand EF, Moroni G, Mosca M, Mucke J, Mukhtyar CB, Nagy G, Navarra S, Parodis I, Pego-Reigosa JM, Petri M, Pons-Estel BA, Schneider M, Smolen JS, Svenungsson E, Tanaka Y, Tektonidou MG, Teng YO, Tincani A, Vital EM, van Vollenhoven RF, Wincup C, Bertsias G, Boumpas DT. Fanouriakis A, et al. Among authors: teng yo. Ann Rheum Dis. 2024 Jan 2;83(1):15-29. doi: 10.1136/ard-2023-224762. Ann Rheum Dis. 2024. PMID: 37827694
Strategies for promoting tendon-bone healing: Current status and prospects.
Yang C, Teng Y, Geng B, Xiao H, Chen C, Chen R, Yang F, Xia Y. Yang C, et al. Among authors: teng y. Front Bioeng Biotechnol. 2023 Jan 27;11:1118468. doi: 10.3389/fbioe.2023.1118468. eCollection 2023. Front Bioeng Biotechnol. 2023. PMID: 36777256 Free PMC article. Review.
Safety and Efficacy of Long-Term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial.
Saxena A, Ginzler EM, Gibson K, Satirapoj B, Santillán AEZ, Levchenko O, Navarra S, Atsumi T, Yasuda S, Chavez-Perez NN, Arriens C, Parikh SV, Caster DJ, Birardi V, Randhawa S, Lisk L, Huizinga RB, Teng YKO. Saxena A, et al. Among authors: teng yko. Arthritis Rheumatol. 2024 Jan;76(1):59-67. doi: 10.1002/art.42657. Epub 2023 Sep 15. Arthritis Rheumatol. 2024. PMID: 37466424
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial.
Ma F, Yan M, Li W, Ouyang Q, Tong Z, Teng Y, Wang Y, Wang S, Geng C, Luo T, Zhong J, Zhang Q, Liu Q, Zeng X, Sun T, Mo Q, Liu H, Cheng Y, Cheng J, Wang X, Nie J, Yang J, Wu X, Wang X, Li H, Ye C, Dong F, Wu S, Zhu X, Xu B; PHILA Investigators. Ma F, et al. Among authors: teng y. BMJ. 2023 Oct 31;383:e076065. doi: 10.1136/bmj-2023-076065. BMJ. 2023. PMID: 37907210 Free PMC article. Clinical Trial.
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Zhang P, Zhang Q, Tong Z, Sun T, Li W, Ouyang Q, Hu X, Cheng Y, Yan M, Pan Y, Teng Y, Yan X, Wang Y, Xie W, Zeng X, Wang X, Hu C, Geng C, Zhang H, Li W, Wu X, Zhong J, Xu J, Shi Y, Wei W, Bayaxi N, Zhu X, Xu B. Zhang P, et al. Among authors: teng y. Lancet Oncol. 2023 Jun;24(6):646-657. doi: 10.1016/S1470-2045(23)00172-9. Epub 2023 May 11. Lancet Oncol. 2023. PMID: 37182538 Clinical Trial.
3,124 results